SYD985 | trastuzumab vc-seco-DUBA | NCT02277717 (Clinical Trial)

Study Title
First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients. NCT02277717

Trial Description
The purpose of this study is to evaluate the safety of a new medicinal drug SYD985 at different dose levels in patients with cancer, to understand how SYD985 is handled by the body and to evaluate the effect of SYD985 on the cancer.

This trial is sponsored by Synthon Biopharmaceuticals® BV

Study Data

  • Condition: Solid Tumors
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 160
  • Start: October 2014
  • Estimated Completion: December 2018
  • Last verified: January 2018

Study Schematic

NCT02277717

Click here to Return to Drug map


Last Editorial review: February 2018
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.